Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal ...
Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase ...
Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for ...
Agreement supports potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration ...
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily ...
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal ...
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) ...
BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast ...
Accessibility Tools
